NEO
Overvalued by 194% based on the discounted cash flow analysis.
Market cap | $1.79 Billion |
---|---|
Enterprise Value | $1.94 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $-0.67 |
Beta | 1.86 |
Outstanding Shares | 127,711,930 |
Avg 30 Day Volume | 586,755 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -21.23 |
---|---|
PEG | 175.06 |
Price to Sales | 3.43 |
Price to Book Ratio | 1.96 |
Enterprise Value to Revenue | 3.18 |
Enterprise Value to EBIT | -20.57 |
Enterprise Value to Net Income | -24 |
Total Debt to Enterprise | 0.28 |
Debt to Equity | 0.58 |
No data
No data
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The ...